☆ 4.6 Review

Peptide-based approaches to directly target alpha-synuclein in Parkinson's disease

MOLECULAR NEURODEGENERATION (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Biochemistry & Molecular Biology

A guide to studying protein aggregation

Joelle A. J. Housmans et al.

Summary: Disruptions or instabilities in protein folding can lead to the accumulation of misfolded proteins and the formation of protein aggregates, which are associated with human diseases and pose challenges in biopharmaceutical manufacturing. However, protein aggregates can also be functional and have applications in biomaterials, therapeutics, and food improvement. Understanding the steps involved in protein aggregation is crucial for developing diagnostic methods, treatments, and applications in various fields. The study of protein aggregation is challenging due to its complex and dynamic nature.

FEBS JOURNAL (2023)

添加到收藏夹

Article Clinical Neurology

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

Andrew Siderowf et al.

LANCET NEUROLOGY (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Phosphorylation of a-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson's disease

Hideaki Matsui et al.

Summary: This study found that phosphorylation of a-Synuclein at T64 was increased in both Parkinson's disease models and human PD brains. The T64D phosphomimetic mutation led to the formation of a-Synuclein oligomers with a similar structure to those with the A53T mutation, and it induced mitochondrial dysfunction, lysosomal disorder, cell death, and neurodegeneration. These findings suggest a pathogenic role of a-Synuclein phosphorylation at T64 in Parkinson's disease.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease

Satra Nim et al.

Summary: This study demonstrates that disruption of the interaction between CHMP2B and alpha-synuclein by a peptide inhibitor can alleviate neurodegeneration in Parkinson's disease models. The accumulation of alpha-synuclein and its toxic forms is implicated in dopaminergic neurodegeneration. The peptide inhibitor identified in this study restores endolysosomal function and reduces alpha-synuclein levels in various models, suggesting that targeting the alpha-synuclein-CHMP2B interaction could be a potential therapeutic strategy.

NATURE COMMUNICATIONS (2023)

添加到收藏夹

Article Chemistry, Multidisciplinary

An N-terminal alpha-synuclein fragment binds lipid vesicles to modulate lipid-induced aggregation

Richard M. Meade et al.

Summary: Misfolding and aggregation of alpha-synuclein (aS) into toxic conformations is involved in neurodegenerative diseases. This study demonstrates that a peptide based on the first 25 residues of aS can inhibit its aggregation process, providing a potential route for the treatment or prevention of these diseases.

CELL REPORTS PHYSICAL SCIENCE (2023)

添加到收藏夹

Article Multidisciplinary Sciences

Development of a hydroxyflavone-labelled 4554W peptide probe for monitoring & alpha;S aggregation

Kathryn J. C. Watt et al.

Summary: Parkinson's disease is the second most common neurodegenerative disease, but there are currently no disease-modifying treatments available. Diagnosis at the earliest stages and monitoring disease progression at a biochemical level are also lacking.

SCIENTIFIC REPORTS (2023)

添加到收藏夹

Review Pharmacology & Pharmacy

Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease

Hilary Grosso Jasutkar et al.

Summary: This article discusses various approaches to prevent and mitigate alpha-synuclein toxicity in Parkinson's disease, including clearing its aggregates, inhibiting its misfolding and aggregation, reducing its expression level, and enhancing cellular clearance mechanisms. It also discusses the therapeutics in development and the challenges and opportunities in the field.

PHARMACOLOGICAL REVIEWS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Library-Derived Peptide Aggregation Modulators of Parkinson?s Disease Early-Onset ?-Synuclein Variants

Kathryn J. C. Watt et al.

Summary: This study identified five peptides that have inhibitory effects on the aggregation of Parkinson's disease (PD) related protein variants. These peptides not only reduce the aggregation of PD-associated proteins, but also show the same efficacy when incubated with other variants. Additionally, the optimized peptide 4554W(N6A) is highly effective against wild-type protein and several single-point mutant forms, providing a suitable baseline for further PD therapeutic research.

ACS CHEMICAL NEUROSCIENCE (2022)

添加到收藏夹

Review Neurosciences

LRRK2 and idiopathic Parkinson's disease

Emily M. Rocha et al.

Summary: The etiology of idiopathic Parkinson's disease involves multiple factors, including genetics and environmental exposures. LRRK2 plays an important role in iPD, regardless of mutations, by influencing kinase activation and substrate phosphorylation, which contribute to the pathogenesis.

TRENDS IN NEUROSCIENCES (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

A penetratin-derived peptide reduces the membrane permeabilization and cell toxicity of ?-synuclein oligomers

Mitra Pirhaghi et al.

Summary: This study identified nine peptides with high specificity and affinity for α-synuclein oligomers (αSOs) using peptide arrays. Peptides p194, p235, and p249 diverted α-synuclein aggregation from fibrils to amorphous aggregates with reduced II-structures and increased random coil content. In addition, a non-aggregating peptide p216 showed 12-fold higher binding affinity to αSOs than to α-synuclein monomers. These findings suggest that p216 is a promising starting point for developing peptides targeting toxic αSOs in Parkinson's disease.

JOURNAL OF BIOLOGICAL CHEMISTRY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Designer D-peptides targeting the N-terminal region of α-synuclein to prevent parkinsonian-associated fibrilization and cytotoxicity

John R. Horsley et al.

Summary: This study demonstrates the effectiveness of using D-peptide inhibitors targeting the NTR region of α-synuclein (α S) to prevent aggregation and fibril formation, and reduce the cytotoxicity of α S aggregates. This approach provides a potential strategy for treating Parkinson's disease.

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Human antimicrobial peptide LL-37 contributes to Alzheimer's disease progression

Xue Chen et al.

Summary: This study reveals that the antimicrobial peptide LL-37 promotes the membrane translocation and integration of CLIC1, leading to microglial hyperactivation and neuroinflammation in Alzheimer's disease. The findings suggest that LL-37 may act as an endogenous agonist of CLIC1, driving the progression of AD.

MOLECULAR PSYCHIATRY (2022)

添加到收藏夹

Article Multidisciplinary Sciences

Single residue modulators of amyloid formation in the N-terminal P1-region of α-synuclein

Sabine M. Ulamec et al.

Summary: In this study, the authors characterized the impact of amino acid substitution on alpha-synuclein aggregation. They found that residues 38 and 42 within the P1 region of alpha-synuclein influence amyloid formation.

NATURE COMMUNICATIONS (2022)

添加到收藏夹

Article Chemistry, Multidisciplinary

Rationally designed helical peptidomimetics disrupt α-synuclein fibrillation

Clementine E. Bavinton et al.

Summary: In this study, a supramolecular approach using designed peptidomimetics was employed to recognize and slow down the aggregation and misfolding of α-Syn protein, which is related to the pathogenesis of Parkinson's disease.

CHEMICAL COMMUNICATIONS (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Therapeutic peptides: current applications and future directions

Lei Wang et al.

Summary: Peptide drug development has achieved significant progress in the past decade, thanks to new production, modification, and analytic technologies. These advancements have addressed the inherent limitations of peptides and have resulted in achievements in various therapeutic areas.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

A Downsized and Optimised Intracellular Library-Derived Peptide Prevents Alpha-Synuclein Primary Nucleation and Toxicity Without Impacting Upon Lipid Binding

Richard M. Meade et al.

Summary: A peptide inhibitor was derived from a cell library screen to block aggregation of alpha-synuclein (α S) and its conversion into toxic species. Truncation and alanine scan analysis were used to determine inhibitory residues and improve peptide efficacy without disrupting α S lipid-binding. This work aims to develop a potent peptide antagonist of α S pathogenicity while preserving its native function.

JOURNAL OF MOLECULAR BIOLOGY (2021)

添加到收藏夹

Article Clinical Neurology

A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease

Hui Liu et al.

Summary: A novel heterozygous A30G mutation of the SNCA gene was identified in five affected individuals from three Greek families, suggesting a founder effect. This mutation had local effects on the structure and function of alpha-synuclein.

MOVEMENT DISORDERS (2021)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Trends in peptide drug discovery

Markus Muttenthaler et al.

Summary: This Perspective summarizes key trends in peptide drug discovery and development, including human hormones, elegant medicinal chemistry and rational design strategies, peptide drugs derived from nature, and major breakthroughs in molecular biology and peptide chemistry. It also emphasizes lessons from earlier approaches that are still relevant today and discusses emerging strategies impact on peptide drug discovery.

NATURE REVIEWS DRUG DISCOVERY (2021)

添加到收藏夹

Article Biology

Development of an α-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models

Jack Wuyang Jin et al.

Summary: In two mouse models of Parkinson's disease, Jin et al develop and characterise a blood-brain barrier and plasma membrane-permeable alpha-synuclein knockdown peptide, Tat-beta syn-degron. They show that Tat-beta syn-degron decreases alpha-synuclein aggregates and microglial activation as well as reducing neuronal damage and motor impairment. This study demonstrates the therapeutic potential of Tat-beta syn-degron in Parkinson's disease treatment.

COMMUNICATIONS BIOLOGY (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019

Zejin Ou et al.

Summary: The incidence, prevalence, and years lived with disability (YLDs) of Parkinson's disease (PD) have shown increasing trends globally from 1990 to 2019. Most regions and countries have observed an upward trend in the burden of PD, particularly in relation to the aging population.

FRONTIERS IN PUBLIC HEALTH (2021)

添加到收藏夹

Review Clinical Neurology

Challenges in the diagnosis of Parkinson's disease

Eduardo Tolosa et al.

Summary: Parkinson's disease is the second most common neurodegenerative disease, with efforts being made to accurately diagnose and characterize it, including validation of diagnostic criteria and identification of genetic subtypes. Progress in diagnostic biomarkers has opened up possibilities for earlier identification, recognition of diverse subtypes, and development of novel treatments.

LANCET NEUROLOGY (2021)

添加到收藏夹

Article Neurosciences

Identification of Two Novel Peptides That Inhibit α-Synuclein Toxicity and Aggregation

Blagovesta Popova et al.

Summary: The study identified short peptides in budding yeast that inhibit α Syn aggregation and toxicity, reducing the accumulation of toxic species in living cells and increasing cell viability. Two synthetic peptides, K84s and K102s, significantly inhibited α Syn oligomerization and aggregation, showing promising potential for future therapeutic interventions.

FRONTIERS IN MOLECULAR NEUROSCIENCE (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

A Mini-Review on the Effectiveness of Peptoids as Therapeutic Interventions against Neurodegenerative Diseases

Subha Sankar Paul et al.

Summary: Neurodegenerative diseases have become one of the major age-related diseases. N-substituted glycines or peptoids have emerged as versatile peptidomimetics with greater cellular permeability, less immunogenicity, and intranasal administration capability.

CURRENT PROTEIN & PEPTIDE SCIENCE (2021)

添加到收藏夹

Article Multidisciplinary Sciences

α-Helical peptidic scaffolds to target α-synuclein toxic species with nanomolar affinity

Jaime Santos et al.

Summary: Researchers have identified a class of peptides that can bind toxic α-synuclein oligomers and amyloid fibrils without interfering with monomeric functional protein, preventing further aggregation and associated cell damage.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

A SUMO1-Derived Peptide Targeting SUMO-Interacting Motif Inhibits α-Synuclein Aggregation

Zhaohui Liang et al.

Summary: A SUMO1(15-55) peptide inhibitor has been developed to suppress alpha-synuclein aggregation and reduce alpha-synuclein-induced cytotoxicity in cell-based and Drosophila disease models. Molecular modeling and binding studies revealed the mode of interaction between the inhibitor and alpha-synuclein, showing binding via SUMO-interacting motifs and a hydrophobic binding groove.

CELL CHEMICAL BIOLOGY (2021)

添加到收藏夹

Article Biology

Inhibition of synucleinopathic seeding by rationally designed inhibitors

Smriti Sangwan et al.

ELIFE (2020)

添加到收藏夹

Review Neurosciences

PINK1 and Parkin mitochondrial quality control: a source of regional vulnerability in Parkinson's disease

Preston Ge et al.

MOLECULAR NEURODEGENERATION (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

A short motif in the N-terminal region of α-synuclein is critical for both aggregation and function

Ciaran P. A. Doherty et al.

NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)

添加到收藏夹

Article Chemistry, Physical

Inhibition of aggregation and toxicity of α-synuclein in the presence of copper by an N-methylated peptide

Binbin Zhou et al.

JOURNAL OF MOLECULAR STRUCTURE (2020)

添加到收藏夹

Article Clinical Neurology

A novelSNCAE83Q mutation in a case of dementia with Lewy bodies and atypical frontotemporal lobar degeneration

Alifiya Kapasi et al.

NEUROPATHOLOGY (2020)

添加到收藏夹

Article Neurosciences

Insights Into Peptide Inhibition of Alpha-Synuclein Aggregation

James H. Torpey et al.

FRONTIERS IN NEUROSCIENCE (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Novel self-replicating α-synuclein polymorphs that escape ThT monitoring can spontaneously emerge and acutely spread in neurons

Francesca De Giorgi et al.

SCIENCE ADVANCES (2020)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Library Derived 4554W Peptide Inhibits Primary Nucleation of α-Synuclein

Richard M. Meade et al.

JOURNAL OF MOLECULAR BIOLOGY (2020)

添加到收藏夹

Review Neurosciences

The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson's Diseases

Jiaming Zhang et al.

FRONTIERS IN NEUROSCIENCE (2019)

添加到收藏夹

Review Biochemistry & Molecular Biology

The physiological role of α-synuclein and its relationship to Parkinson's Disease

David Sulzer et al.

JOURNAL OF NEUROCHEMISTRY (2019)

添加到收藏夹

Review Neurosciences

Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles

Richard M. Meade et al.

MOLECULAR NEURODEGENERATION (2019)

添加到收藏夹

Article Biology

Two new polymorphic structures of human full-length alpha-synuclein fibrils solved by cryo-electron microscopy

Ricardo Guerrero-Ferreira et al.

ELIFE (2019)

添加到收藏夹

Review Clinical Neurology

International Parkinson and Movement Disorder Society Evidence-Based Medicine Review: Update on Treatments for the Motor Symptoms of Parkinson's Disease

Susan H. Fox et al.

MOVEMENT DISORDERS (2018)

添加到收藏夹

Article Cell Biology

Amyloid fibril structure of α-synuclein determined by cryoelectron microscopy

Yaowang Li et al.

CELL RESEARCH (2018)

添加到收藏夹

Article Geriatrics & Gerontology

Homozygous alpha-synuclein p.A53V in familial Parkinson's disease

Hiroyo Yoshino et al.

NEUROBIOLOGY OF AGING (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Structural basis of membrane disruption and cellular toxicity by α-synuclein oligomers

Giuliana Fusco et al.

SCIENCE (2017)

添加到收藏夹

Article Biochemistry & Molecular Biology

The inhibitory effects of biomimetically designed peptides on α-synuclein aggregation

Niloofar Rezaeian et al.

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2017)

添加到收藏夹

Review Medicine, General & Internal

An update on the diagnosis and treatment of Parkinson disease

Philippe Rizek et al.

CANADIAN MEDICAL ASSOCIATION JOURNAL (2016)

添加到收藏夹

Article Chemistry, Multidisciplinary

Self-Assembled Cyclic D,L-α-Peptides as Generic Conformational Inhibitors of the α-Synuclein Aggregation and Toxicity: In Vitro and Mechanistic Studies

Marina Chemerovski-Glikman et al.

CHEMISTRY-A EUROPEAN JOURNAL (2016)

添加到收藏夹

Review Biochemistry & Molecular Biology

Alpha-synuclein: relating metals to structure, function and inhibition

J. S. McDowall et al.

METALLOMICS (2016)

添加到收藏夹

Review Neurosciences

α-Synuclein-Based Animal Models of Parkinson's Disease: Challenges and Opportunities in a New Era

Naomi P. Visanji et al.

TRENDS IN NEUROSCIENCES (2016)

添加到收藏夹

Article Multidisciplinary Sciences

β-Synuclein suppresses both the initiation and amplification steps of α-synuclein aggregation via competitive binding to surfaces

James W. P. Brown et al.

SCIENTIFIC REPORTS (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Intracellular Screening of a Peptide Library to Derive a Potent Peptide Inhibitor of α-Synuclein Aggregation

Harish Cheruvara et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2015)

添加到收藏夹

Article Multidisciplinary Sciences

Structure of the toxic core of α-synuclein from invisible crystals

Jose A. Rodriguez et al.

NATURE (2015)

添加到收藏夹

Article Chemistry, Multidisciplinary

Binding interactions of agents that alter α-synuclein aggregation

K. Sivanesam et al.

RSC ADVANCES (2015)

添加到收藏夹

Article Genetics & Heredity

Clinical and imaging findings in Parkinson disease associated with the A53E SNCA mutation

Mika H. Martikainen et al.

NEUROLOGY-GENETICS (2015)

添加到收藏夹

Article Clinical Neurology

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials

Markus Mandler et al.

ACTA NEUROPATHOLOGICA (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Retro-inversal of Intracellular Selected β-Amyloid-Interacting Peptides: Implications for a Novel Alzheimer's Disease Treatment

Nicola Acerra et al.

BIOCHEMISTRY (2014)

添加到收藏夹

Article Biochemistry & Molecular Biology

Divergent effects of the H5OQ and G51D SNCA mutations on the aggregation of α-synuclein

Nicola J. Rutherford et al.

JOURNAL OF NEUROCHEMISTRY (2014)

添加到收藏夹

Article Geriatrics & Gerontology

A novel α-synuclein mutation A53E associated with atypical multiple system atrophy and Parkinson's disease-type pathology

Petra Pasanen et al.

NEUROBIOLOGY OF AGING (2014)

添加到收藏夹

Article Clinical Neurology

α-Synucleinopathy associated with G51D SNCA mutation: a link between Parkinson's disease and multiple system atrophy?

Aoife P. Kiely et al.

ACTA NEUROPATHOLOGICA (2013)

添加到收藏夹

Article Clinical Neurology

G51D α-Synuclein mutation causes a novel Parkinsonian-pyramidal syndrome

Suzanne Lesage et al.

ANNALS OF NEUROLOGY (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

The Parkinson's Disease-Associated H50Q Mutation Accelerates α-Synuclein Aggregation in Vitro

Dhiman Ghosh et al.

BIOCHEMISTRY (2013)

添加到收藏夹

Review Biochemistry & Molecular Biology

The Future of Peptide-based Drugs

David J. Craik et al.

CHEMICAL BIOLOGY & DRUG DESIGN (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

Partial Peptide of α-Synuclein Modified with Small-Molecule Inhibitors Specifically Inhibits Amyloid Fibrillation of α-Synuclein

Wataru Yoshida et al.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2013)

添加到收藏夹

Review Immunology

Little Peptide, Big Effects: The Role of LL-37 in Inflammation and Autoimmune Disease

J. Michelle Kahlenberg et al.

JOURNAL OF IMMUNOLOGY (2013)

添加到收藏夹

Article Clinical Neurology

Alpha-synuclein p.H50Q, a novel pathogenic mutation for Parkinson's disease

Silke Appel-Cresswell et al.

MOVEMENT DISORDERS (2013)

添加到收藏夹

Editorial Material Clinical Neurology

A NOVEL α-SYNUCLEIN MISSENSE MUTATION IN PARKINSON DISEASE

Christos Proukakis et al.

NEUROLOGY (2013)

添加到收藏夹

Article Biochemistry & Molecular Biology

O-GlcNAc Modification Prevents Peptide-Dependent Acceleration of α-Synuclein Aggregation

Nicholas P. Marotta et al.

CHEMBIOCHEM (2012)

添加到收藏夹

Article Neurosciences

Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission

Eun-Jin Bae et al.

JOURNAL OF NEUROSCIENCE (2012)

添加到收藏夹

Article Medicine, Research & Experimental

Genetics of Parkinson's Disease

Christine Klein et al.

COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2012)

添加到收藏夹

Review Pharmacology & Pharmacy

Peptide and peptoid foldamers in medicinal chemistry

W. Seth Horne

EXPERT OPINION ON DRUG DISCOVERY (2011)

添加到收藏夹

Article Biochemistry & Molecular Biology

Antimicrobial Activity of Community-associated Methicillin-resistant Staphylococcus aureus Is Caused by Phenol-soluble Modulin Derivatives

Hwang-Soo Joo et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2011)

添加到收藏夹

Article Multidisciplinary Sciences

α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation

Tim Bartels et al.

NATURE (2011)

添加到收藏夹

Review Biotechnology & Applied Microbiology

Cell death assays for drug discovery

Oliver Kepp et al.

NATURE REVIEWS DRUG DISCOVERY (2011)

添加到收藏夹

Article Multidisciplinary Sciences

Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease

Eliezer Masliah et al.

PLOS ONE (2011)

添加到收藏夹

Article Clinical Neurology

Clinical Progression in Parkinson Disease and the Neurobiology of Axons

Hsiao-Chun Cheng et al.

ANNALS OF NEUROLOGY (2010)

添加到收藏夹

Review Chemistry, Medicinal

Design and development of peptides and peptide mimetics as antagonists for therapeutic intervention

Jody M. Mason

FUTURE MEDICINAL CHEMISTRY (2010)

添加到收藏夹

Article Multidisciplinary Sciences

Inhibiting α-Synuclein Oligomerization by Stable Cell-Penetrating β-Synuclein Fragments Recovers Phenotype of Parkinson's Disease Model Flies

Ronit Shaltiel-Karyo et al.

PLOS ONE (2010)

添加到收藏夹

Article Biochemistry & Molecular Biology

β-Sheet-breaking peptides inhibit the fibrillation of human α-synuclein

You Soon Kim et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

α-Synuclein Aggregation and Ser-129 Phosphorylation-dependent Cell Death in Oligodendroglial Cells

Christine L. Kragh et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

Rapid selection of cyclic peptides that reduce α-synuclein toxicity in yeast and animal models

Joshua A. Kritzer et al.

NATURE CHEMICAL BIOLOGY (2009)

添加到收藏夹

Article Multidisciplinary Sciences

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of α-synuclein

Paula Desplats et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

添加到收藏夹

Editorial Material Multidisciplinary Sciences

Is Parkinson's disease a prion disorder?

C. Warren Olanow et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)

添加到收藏夹

Article Biochemistry & Molecular Biology

Sequence determinants regulating fibrillation of human α-synuclein

Hyun-Jung Koo et al.

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)

添加到收藏夹

Review Clinical Neurology

Parkinson's disease: clinical features and diagnosis

J. Jankovic

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)

添加到收藏夹

Article Chemistry, Multidisciplinary

Design of an N-methylated peptide inhibitor of α-synuclein aggregation guided by solid-state NMR

Jillian Madine et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2008)

添加到收藏夹

Article Biochemistry & Molecular Biology

N-methylated peptide inhibitors of β-amyloid aggregation and toxicity.: Optimization of the inhibitor structure

Nicoleta Kokkoni et al.

BIOCHEMISTRY (2006)

添加到收藏夹

Article Biochemistry & Molecular Biology

Specification of SUMO1- and SUMO2-interacting motifs

Christina-Maria Hecker et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2006)

添加到收藏夹

Article Biochemistry & Molecular Biology

Small ubiquitin-like modifier (SUMO) recognition of a SUMO binding motif - A reversal of the bound orientation

J Song et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2005)

添加到收藏夹

Article Chemistry, Multidisciplinary

Phosphorylation of an α-synuclein peptide fragment enhances metal binding

LL Liu et al.

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)

添加到收藏夹

Article Biochemistry & Molecular Biology

The E46K mutation in α-synuclein increases amyloid fibril formation

EA Greenbaum et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2005)

添加到收藏夹

Article Neurosciences

Inhibition of fibril formation and toxicity of a fragment of α-synuclein by an N-methylated peptide analogue

AM Bodles et al.

NEUROSCIENCE LETTERS (2004)

添加到收藏夹

Article Clinical Neurology

The new mutation, E46K, of α-synuclein causes Parkinson and Lewy body dementia

JJ Zarranz et al.

ANNALS OF NEUROLOGY (2004)

添加到收藏夹

Article Medicine, General & Internal

α-synuclein locus duplication as a cause of familial Parkinson's disease

MC Chartier-Harlin et al.

LANCET (2004)

添加到收藏夹

Article Medicine, General & Internal

Causal relation between α-synuclein gene duplication and familial Parkinson's disease

P Ibáñez et al.

LANCET (2004)

添加到收藏夹

Article Biochemistry & Molecular Biology

A strategy for designing inhibitors of α-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders

OMA El-Agnaf et al.

FASEB JOURNAL (2004)

添加到收藏夹

Article Multidisciplinary Sciences

α-synuclein locus triplication causes Parkinson's disease

AB Singleton et al.

SCIENCE (2003)

添加到收藏夹

Article Biochemistry & Molecular Biology

β-synuclein inhibits formation of α-synuclein protofibrils:: A possible therapeutic strategy against Parkinson's disease

JY Park et al.

BIOCHEMISTRY (2003)

添加到收藏夹

Article Cell Biology

α-Synuclein is phosphorylated in synucleinopathy lesions

H Fujiwara et al.

NATURE CELL BIOLOGY (2002)

添加到收藏夹

Article Hematology

Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3

OE Sorensen et al.

BLOOD (2001)

添加到收藏夹

Article Biochemistry & Molecular Biology

A hydrophobic stretch of 12 amino acid residues in the middle of α-synuclein is essential for filament assembly

BI Giasson et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2001)

添加到收藏夹

Article Biochemistry & Molecular Biology

Inhibition of toxicity in the β-amyloid peptide fragment β-(25-35) using N-methylated derivatives -: A general strategy to prevent amyloid formation

E Hughes et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2000)

添加到收藏夹

Article Biochemistry & Molecular Biology

Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid

KA Conway et al.

BIOCHEMISTRY (2000)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.